1-[2-({(2R,5R)-2-methyl-5-[(1-oxo-1,3-dihydrofuro[3,4-c]pyridin-4-yl)oxy]piperidin-1-yl}carbonyl)phenyl]cyclopropanecarbonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[2-({(2R,5R)-2-methyl-5-[(1-oxo-1,3-dihydrofuro[3,4-c]pyridin-4-yl)oxy]piperidin-1-yl}carbonyl)phenyl]cyclopropanecarbonitrile
• 英文别名: US9556190, Example 31；1-[2-[(2R,5R)-2-methyl-5-[(1-oxo-3H-furo[3,4-c]pyridin-4-yl)oxy]piperidine-1-carbonyl]phenyl]cyclopropane-1-carbonitrile
• 化学式: C₂₄H₂₃N₃O₄
• 分子量: 417.464
• InChiKey: YOYHOMQHRBFXIN-HZPDHXFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  92.5
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS PIPÉRIDINYLOXY LACTONE SERVANT D'ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015095442A1

  公开（公告）日：2015-06-25

  The present invention is directed to piperidinyloxy lactone compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the piperidinyloxy lactone compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对奥雷克星受体的拮抗剂-哌啶氧代内酯化合物。本发明还涉及所述哌啶氧代内酯化合物在潜在的涉及奥雷克星受体的神经和精神障碍和疾病的治疗或预防中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及奥雷克星受体的疾病中的用途。
• PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160318944A1

  公开（公告）日：2016-11-03

  The present invention is directed to piperidinyloxy lactone compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the piperidinyloxy lactone compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
• US9556190B2
  申请人：——

  公开号：US9556190B2

  公开（公告）日：2017-01-31